Welcome
Support Centre
09 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
A randomised trial comparing epirubicin, cisplatin and protracted venous infusion (PVI) 5-Fluorouracil (5FU) (ECF) to 5FU, Etoposide Leucovorin (FELU) in patients with inoperable or metastatic biliary cancer
ISRCTN ISRCTN73941125
ClinicalTrials.gov identifier
Public title A randomised trial comparing epirubicin, cisplatin and protracted venous infusion (PVI) 5-Fluorouracil (5FU) (ECF) to 5FU, Etoposide Leucovorin (FELU) in patients with inoperable or metastatic biliary cancer
Scientific title
Acronym N/A
Serial number at source RMH E/C 1323
Study hypothesis Not provided at time of registration
Lay summary
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Biliary Tract
Participants - inclusion criteria 1. Histological locally advanced or metastatic adenocarcinoma, squamous carcinoma or undifferentiated carcinoma of the gallbladder, intra/extra-hepatic bile ducts or Ampulla of Vater
2. Measurable disease on Computed Tomography (CT), Magnetic Resonance Imaging (MRI) or radiograph
Participants - exclusion criteria Not provided at time of registration
Anticipated start date 01/01/2000
Anticipated end date 31/12/2005
Status of trial Completed
Patient information material
Target number of participants Not provided at time of registration
Interventions 1. FELU: 5FU 600 mg/m2 IV bolus 1-3 every 3 weeks Etoposide 120 mg/m2 IV infusion over 40 min days 1-3 every 3 weeks Leucovorin 60 mg/m2 IV bolus days 1-3 every 3 weeks
2. ECF: 5FU 200 mg/m2 daily continuous infusion for 24 weeks. Epirubicin 50 mg/m2 3-weekly IV bolus Cisplatin 60 mg/m2 3 weekly
Primary outcome measure(s) Not provided at time of registration
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Royal Marsden Hospital (UK)
Trial website
Publications
Contact name Dr  -  -
  Address UKCCCR
Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
  City/town London
  Zip/Postcode NW1 2DA
  Country United Kingdom
  Tel +44 (0) 20 7670 4723
  Fax +44 (0) 20 7670 4818
  Email
Sponsor The Royal Marsden NHS Foundation Trust (UK)
  Address Downs Road
  City/town Sutton
  Zip/Postcode SM2 5PT
  Country United Kingdom
Date applied 19/08/2002
Last edited 23/02/2011
Date ISRCTN assigned 19/08/2002
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central